Prediagnostic concentrations of plasma genistein and prostate cancer risk in 1,605 men with prostate cancer and 1,697 matched control participants in EPIC

Cancer Causes and Control

Volumn 23, Issue 7, 2012, Pages 1163-1171

  Travis, Ruth C ^a   Allen, Naomi E ^a   Appleby, Paul N ^a   Price, Alison ^a   Kaaks, Rudolf ^b   Chang Claude, Jenny ^b   Boeing, Heiner ^c   Aleksandrova, Krasimira ^c   Tjønneland, Anne ^d   Johnsen, Nina Føns ^d   Overvad, Kim ^e,f   Ramon Quiros J ^g   González, Carlos A ^h   Molina Montes, Esther ^i,j   Sánchez, Maria José ^i,j   Larrañaga, Nerea ^j,k   Castaño, José María Huerta ^l   Ardanaz, Eva ^m   Khaw, Kay Tee ⁿ   Wareham, Nick ^o   Trichopoulou, Antonia ^p,q   Karapetyan, Tina ^p   Rafnsson, Snorri Bjorn ^p   Palli, Domenico ^r   Krogh, Vittorio ^s   Tumino, Rosario ^t   Vineis, Paolo ^u,v   Bueno De Mesquita, H Bas ^w,x   Stattin, Pär ^y,z   Johansson, Mattias ^aa,ab   Fedirko, Veronika ^aa   Norat, Teresa ^u   Siddiq, Afshan ^u   Riboli, Elio ^u   Key, Timothy J ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^d INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

^g PUBLIC HEALTH DIRECTORATE   (Spain)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁱ ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^j CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^k Basque Government   (Spain)

^l Murcia Regional Health Authority   (Spain)

^m INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

ⁿ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^o MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^p HELLENIC HEALTH FOUNDATION   (Greece)

^q UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^r CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^s NATIONAL CANCER INSTITUTE   (Italy)

^t CIVILE M P AREZZO HOSPITAL   (Italy)

^u IMPERIAL COLLEGE LONDON   (United Kingdom)

^v HuGeF Foundation   (Italy)

^w NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^x UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^y MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^z UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^aa INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^ab UMEÅ UNIVERSITY   (Sweden)

more..

Author keywords

Genistein; Isoflavone; Phyto estrogen; Plasma; Prospective; Prostate cancer

Indexed keywords

GENISTEIN; ISOFLAVONE;

ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; AGED; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EUROPE; GENISTEIN; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUESTIONNAIRES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TANDEM MASS SPECTROMETRY;

EID: 84862486948     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-012-9985-y     Document Type: Article

References (23)

1. Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM (2009) Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer 61:598-606
2. Yan L, Spitznagel EL (2009) Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr 89:1155-1163
3. Perabo FG, Von Low EC, Ellinger J, von Rucker A, Muller SC, Bastian PJ (2008) Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis 11:6-12 (Pubitemid 351250324)
4. Liggins J, Mulligan A, Runswick S, Bingham SA (2002) Daidzein and genistein content of cereals. Eur J Clin Nutr 56:961-966 (Pubitemid 35244172)
5. Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A (2003) Bioavailability of phyto-oestrogens. Br J Nutr 89(Suppl 1):S45-S58 (Pubitemid 36798245)
6. Ozasa K, Nakao M, Watanabe Y, Hayashi K, Miki T, Mikami K et al (2004) Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 95:65-71 (Pubitemid 38208409)
7. Kurahashi N, Iwasaki M, Inoue M, Sasazuki S, Tsugane S (2008) Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center. J Clin Oncol 26:5923-5929
8. Travis RC, Spencer EA, Allen NE, Appleby PN, Roddam AW, Overvad K et al (2009) Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 100:1817-1823
9. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M et al (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5:1113-1124 (Pubitemid 36313608)
10. Grace PB, Mistry NS, Carter MH, Leathem AJ, Teale P (2007) High throughput quantification of phytoestrogens in human urine and serum using liquid chromatography/tandem mass spectrometry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 853:138-146 (Pubitemid 46891342)
11. Rosner B (1982) On the estimation and testing of interclass correlations: the general case of multiple replicates for each variable. Am J Epidemiol 116:722-730
12. StataCorp (2007) Stata statistical software: release 10. StataCorp LP, College Station, TX
13. Peeters PH, Slimani N, van der Schouw YT, Grace PB, Navarro C, Tjonneland A et al (2007) Variations in plasma phytoestrogen concentrations in European adults. J Nutr 137:1294-1300 (Pubitemid 46701925)
14. Ward H, Chapelais G, Kuhnle GG, Luben R, Khaw KT, Bingham S (2008) Lack of prospective associations between plasma and urinary phytoestrogens and risk of prostate or colorectal cancer in the European Prospective into Cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 17:2891-2894
15. McCarty MF (2006) Isoflavones made simple-genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. Med Hypotheses 66:1093-1114
16. D'Ambrosio G, Samani F, Cancian M, De Mola C (2004) Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database. Eur J Cancer Prev 13:383-386 (Pubitemid 39336602)
17. Melia J, Moss S, Johns L (2004) Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 94:51-56 (Pubitemid 38980308)
18. Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schroder FH et al (2003) Effective PSA contamination in the Rotterdam section of the European randomized study of screening for prostate cancer. Int J Cancer 105:394-399 (Pubitemid 36570054)
19. Paez A, Lujan M, Llanes L, Romero I, de la Cal MA, Miravalles E et al (2002) PSA-use in a Spanish industrial area. Eur Urol 41:162-166 (Pubitemid 35428882)
20. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH et al (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Institute 94:981-990 (Pubitemid 34814727)
21. Grace PB, Taylor JI, Low YL, Luben RN, Mulligan AA, Botting NP et al (2004) Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European Prospective Investigation of Cancer and Nutrition-Norfolk. Cancer Epidemiol Biomarkers Prev 13:698-708 (Pubitemid 38737856)
22. Zeleniuch-Jacquotte A, Adlercreutz H, Akhmedkhanov A, Toniolo P (1998) Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period. Cancer Epidemiol Biomarkers Prev 7:885-889 (Pubitemid 28471576)
23. Fraser GE, Franke AA, Jaceldo-Siegl K, Bennett H (2010) Reliability of serum and urinary isoflavone estimates. Biomarkers 15:135-139